First Head & Neck Cancer Patient Treated in France in a Phase I trial with TG4050 (myvac® Platform), Transgene’s Innovative Individualized Immunotherapy
By nh|2021-01-20T14:41:47+01:00January 21st, 2021|Myvac, Press release, TG4050|Comments Off on First Head & Neck Cancer Patient Treated in France in a Phase I trial with TG4050 (myvac® Platform), Transgene’s Innovative Individualized Immunotherapy
About the Author: nh
